We are NOT authorized by Govt of India for Yellow Fever Vaccination

Friday, January 15, 2016

WHAT YOU NEED TO KNOW ABOUT ZIKA VIRUS - IT’S CAUSING BABIES TO BE BORN WITH TINY HEADS

By Alexandra Ossola Posted January 13, 2016



Recently, a new viral outbreak in South America has been getting some attention. It’s called the Zika virus, and it’s spread throughout the continent over the past two years. While scientists work to understand just how the disease affects the body, the virus continues it's northward march: After appearing in Puerto Rico at the end of December, the first case of Zika was just diagnosed on the mainland U.S., near Houston, Texas.

Until a few months ago, you might have never run across the name “Zika.” The virus is named for the Zika forest in Uganda where scientists first identified it in 1947.

Since then, scientists have figured out the basics for how the virus works. Zika spreads through mosquito bites, with symptoms like fever and joint pain that usually appear a few days later. Because of how it spreads and the nature of these symptoms, Zika is often compared to dengue fever, also called “breakbone fever.” But Zika is generally milder—only about one fifth of patients develop any symptoms, and most who do are back to normal within a week. So far, Zika has not caused any deaths. There’s no specific treatment or vaccine for Zika; those infected usually just need to take aspirin, drink water, and get lots of rest.
Researchers, however, have recently found a new, disturbing side effect. In October, epidemiologists studying the current outbreak in Brazil noticed a higher incidence of microcephaly, a rare neurological condition in which babies are born with smaller than normal heads and underdeveloped brains. Microcephaly is usually rare, but in some areas where Zika was particularly common, the condition was popping up many more times than it had in previous years--Brazil public health officials reported that in 2015, 3,000 babies were born with the condition, compared to 20 the year before. They noticed more babies with microcephaly were born to mothers infected with Zika, even if they didn't show any symptoms.
Researchers are still not certain how Zika is triggering the increased incidence of microcephaly. But the connection is causing panic—so much so that the Brazilian government recently told women in the country's northeast, where the epidemic has hit hardest, not to get pregnant for fear of these birth defects.

If scientists have known about Zika for nearly 70 years, why is this the first time they have found a connection between the disease and microcephaly?
For one thing the outbreak, going on for two years in South America, is by far the largest Zika epidemic researchers have ever seen. While individual cases have popped up all over the world, previous outbreaks, in 2007 and 2013, have been limited to a few thousand inhabitants on small islands. “We can’t see the same effects from such a small scale,” says Marie-Claire Paty, an epidemiologist specializing in vector-borne diseases at the French Institute for Public Health Surveillance in Paris. “The difference is that in South America, this is a big outbreak with a lot of inhabitants exposed to risk.”
Studying a disease like this in a lab, Paty adds, is very different from seeing its effects in real world-scenarios. Not only would researchers never think to look at the virus’ effects on pregnant women, studying it in the lab would be ethically fraught.

Outbreaks of mosquito-borne viruses—like Zika and chikungunya—seem to be happening because of globalization. Simply put, it's become easier than ever for people to travel the globe, and the same goes for diseases. There’s debate about how Zika arrived in Brazil, but some experts think a mosquito, hitching a ride on an airplane, brought it during the massive arrival of fans to the 2014 World Cup. Global warming, of course, also seems to play a role, expanding the range at which mosquitos and other disease-carrying insects, like ticks, can live comfortably.
What's the outlook?
The epidemic will likely continue for the foreseeable future, spreading around South and Central America and the Caribbean over the next few months, Paty says. The previous smaller outbreaks, which took place on two islands in the Pacific (Yap, in Micronesia, and in French Polynesia), ended when a large proportion of people had developed immunity after being infected, Paty adds. But with a much larger population at risk, that might not be what curbs the outbreak this time.
Without a vaccine available, officials are working to prevent more infections by warning at-risk populations about Zika. Epidemiologists like Paty will be carefully tracking its trajectory to learn more about how it spreads; other scientists will investigate the connection between Zika and microcephaly.
For now, experts have more questions than answers. That will likely put American officials on edge as Zika makes its way into Puerto Rico and the mainland U.S. (the patient recently diagnosed in Texas likely contracted the disease when traveling in South America). The Centers for Disease Control (CDC), as well as public health agencies in other countries, suggests that people in places where Zika virus has been reported take care to prevent mosquito bites by using insect repellant, wearing long sleeves, and staying in places with air conditioning or screens on windows and doors.

Yellow fever outbreak kills three in Ghana

Three persons are reported to have died following an outbreak of Yellow Fever in the West Gonja district in the Northern Region.
So far 12 cases of the disease have been reported in the district, a statement issued by the Ministry of Health in Accra has said.
The statement, signed by the Head of Public Relations Unit of the ministry, Tony Goodman, also confirmed the outbreak of meningitis in the Tain district in the Brong Ahafo Region.

It said “as at January 6,  2016, 30 suspected cases with seven deaths have been recorded of the meningitis in the district, while a total of 12 cases of Yellow Fever have been reported out of which three have so far died since the end of 2015”.
“Typically with this kind of meningitis, fatality is high but potential for massive spread is low,” the statement added.
It, however, indicated that, “this is not Epidemic Meningococcal Disease or CSM, which is caused by Neisseria meningitides, which has potential for massive and widespread outbreaks”.
 Yellow Fever
Yellow fever is “an acute febrile illness that presents with fever and jaundice (yellowish discolouration of the eyes), muscle pain with prominent backache, and headache”.
It may be associated with bleeding tendencies and the disease is transmitted through the bite of infected mosquitoes (Aedes mosquitoes).
Symptoms appear after an incubation period of three to six days following the bite of the mosquitoes. Most patients improve and their symptoms resolve after three  to four days.
However, about 15 per cent of patients enter a second and more toxic phase within 24 hours of the initial remission. High fever returns and is accompanied by severe multisystem illness, the statement further indicated.
 Meningitis
Meningitis is an inflammation of the lining of the brain and spinal cord (meninges) and its causes include bacterial, viral, parasites and even chemical.
Bacterial meningitis is caused by various bacterial pathogens. Neisseria meningitides, Streptococcus pneumoniae and Haemphilus influenza type B represents the triad responsible for over 80 per cent of all cases of bacterial meningitis
Signs and symptoms of meningitis include sudden onset of severe headache, fever, vomiting, neck stiffness and photophobia (dislike for light). Other symptoms include lethargy, coma and convulsions. In babies, there may be bulging of the anterior fontanelle (soft part of the head).
 Commendation
The Ministry of Health commended the regions and districts where the cases had been reported, describing their responses so far as “appropriate and adequate and we expect these response actions to contain and halt the outbreak”.
“We wish to indicate that the Ministry of Health is doing everything possible to contain the situation and we count on the support and cooperation of all,” the statement assured the public.
- See more at: http://graphic.com.gh/news/general-news/55973-yellow-fever-meningitis-claim-10-lives.html#sthash.aKN1MWjo.dpuf

ACCRA, Jan. 8 (Xinhua) -- An outbreak of yellow fever has killed three people in the West Gonja District of Ghana's Northern Region, health authorities announced on Friday.
Twelve more people are said to be suffering from the disease in the area, some 657 km north of the national capital.
The Ministry of Health (MOH) is making efforts to contain the disease, according to a statement signed by Tony Goodman, Public Relations Officer of the ministry.
"It is worthy of note that the response of the regions and districts so far are appropriate and adequate and we expect these response actions to contain and halt the outbreak," he said in the statement.
Yellow fever is an acute viral hemorrhagic disease transmitted by infected mosquitoes.
It can kill up to 50 percent of victims if adequate treatment is not administered.
There are an estimated 200,000 cases of yellow fever, causing 30,000 deaths worldwide each year, with 90 percent occurring in Africa.
Symptoms of the disease include fever, jaundice, muscle pain with prominent backache, and headache.
Vaccination is the most important preventive measure against the disease.
http://news.xinhuanet.com/english/2016-01/09/c_134992064.htm

Thursday, January 14, 2016

India's First Travel Health Clinic offers Vaccination at your home or office

Yellow Fever Vaccination at Home across India

A unique concept pioneered by TravelSafe Clinics, India
Remember the time when you were sick as a child and grandpa would call home your 'Doctor Uncle'? He would stand beside your bed, check your temperature, do a quick examination and then prescribe some medicines after reassuring your parents and explaining what was wrong with you. He always had a special place in your heart.
Times have changed, but we know the feeling. So at TravelSafe Clinics, we now offer home visits or house-calls for vaccinations, just like your 'family doctor' did couple of decades back. 
Depending on your requirements, our trained medical assistants can provide you the necessary vaccinations in the comfort of your home or office, after you have interacted with our panel of doctors. 
This service is especially tailored for the elderly, those who are immobile and cannot visit a clinic/hospital and for those who are having difficulty taking the time out of their busy schedule to visit a doctor's clinic for their relevant vaccinations.

The charges for the home visit will be as following :
Convenience Charge (in Rupees) : Distance from Chandigarh in kms multiplied by 10 

This will be added to the cost of the Yellow fever vaccination, and will remain same irrespective of the number of people getting vaccinated at a single location.
For distances above 1,000 kms, please call/SMS us at +918010777722 or email mohali@travelsafeclinic.com for custom schedule and charges.

For example, let us say 3 people want to get vaccinated at Amritsar, and cannot come to our clinic. The total charges would be as follows - 
Distance from Chandigarh to Amritsar = 230 kms (Source Google Search) 
Convenience Charge  is 233 * 10 = 2300 Rs
Plus Cost Of Yellow Fever Vaccination at current price (valid as per Jan 2016) : 2900 * 3 people = 8700
TOTAL : 8700+2300 = 11,000 /- only

Please remember that Yellow Fever Vaccination needs to be taken at least 10 days before the date of International Travel, and it remains valid for 10 years.
100 % advance charges would be deposited in the Bank Account of Dr Gaurav Gupta, and the details of the Passport would need to be sent across by email so that the WHO International Certificate of Vaccination can be generated for the persons.

This vaccination service is offered at the sole discretion of TravelSafe Clinics, and on a best effort basis only.
Cold Chain is maintained by using Industry Standard Ice Boxes specifically designed for vaccines.
We follow standards suggested by the National Vaccine Advisory Committee, USA for vaccinations. Read the details here
Vaccines at non traditional sites have been shown to be safe and effective in improving coverage as shown in studies here  and here and is strongly recommended by the Community Guide, USA Government as well.

Friday, January 1, 2016

The World’s First Dengue Fever Vaccine Is Coming to Three Countries

The World’s First Dengue Fever Vaccine Is Coming to Three Countries
A third of the world’s population is at risk of contracting Dengue Fever, a miserable virus that’s a leading cause of illness and death in the tropics. Now, for the first time ever, three countries have approved a promising new vaccine.
To say that Dengue Fever is a global health concern is a gross understatement. The US Centers for Disease Control and Prevention estimates that more than 400 million people are infected with the virus each year. About a half-million of these infections develop into the more severe hemorrhagic dengue fever, which causes about 25,000 deaths around the world annually. The World Health Organization says it’s quickly becoming the most problematic mosquito-borne viral disease in the world. And it’s spreading. The disease has extended its reach 30-fold in just 50 years. 
The World’s First Dengue Fever Vaccine Is Coming to Three Countries

Highlighted regions are at primary risk of dengue outbreaks. The red lines show the potential limits for year-round survival of Aedes aegypti mosquitoes. (Credit: NCAR/UCAR)

Frustratingly, there have never been any vaccines to prevent infection. But as Dina Fine Maron reports in Scientific American, there’s finally cause for hope. A new drug, called Dengvaxia, has been approved for use in three countries, namely Mexico, the Philippines, and Brazil.
The vaccine itself is a live virus comprised of a modified yellow fever virus. It’s genetically engineered to include genes that encode for dengue proteins and coaxes the body’s immune system into producing antibodies that fight all four forms of dengue (DEN-1, DEN-2, DEN-3, DEN-4). The vaccine was developed by the French pharmaceutical company Sanofi. As Maron points out, however, It’s not clear when inoculations will start—or at what price.
This meaningful breakthrough is the result of over two decades of work involving 25 clinical studies in 15 countries around the world. Over 40,000 volunteers worked on the project and some 29,000 volunteers received the vaccine. Other vaccinations are currently in development, but only Dengvaxia has been given the green light. Sanofi’s facilities in France are reportedly capable of producing 100 million vaccine doses annually.
Brazil, which approved the vaccine earlier this week, is particularly poised to benefit greatly from the new drug. The South American country recorded more than 1.4 million cases of dengue in 2015.
“Approval of the first dengue vaccine is an important public health breakthrough with critical importance to our country, which bears the greatest dengue burden in Latin America,” noted Joao Bosco from Brazil’s Institute of Tropical Pathology and Public Health in a Sanofi statement. “The 2015 dengue outbreak is still very present in the minds of Brazilians so Dengvaxia’s approval is a most welcome addition to our ongoing dengue prevention efforts.”
Unfortunately, the vaccine isn’t perfect, nor is it for everyone. In clinical trials it proved effective for about 65-percent of participants aged 9 to 16. It prevented 8 out of 10 hospitalizations and up to 93-percent of severe dengue cases. Dengvaxia can only be used on people age nine to 45 years old who live in areas susceptible to dengue fever. Sadly, and as Maron points out, the vaccine appears to be the least effective among those who need it the most: children under six. 
All that said, we don’t yet know how this news will affect those living in the United States. Cases of dengue have recently been reported in Hawaii, Florida, and Puerto Rico, so the CDC and FDA would be wise to keep a close eye on Dengvaxia and how its deployment—and its potential effectiveness—plays out in other parts of the world.